triazolam has been researched along with Anoxia, Brain in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weaver, JM | 1 |
1 other study available for triazolam and Anoxia, Brain
| Article | Year |
|---|---|
The fallacy of a lifesaving sublingual injection of flumazenil.
Topics: Anesthesia Recovery Period; Antidotes; Benzodiazepines; Conscious Sedation; Drug Overdose; Flumazeni | 2011 |